YMAB Fundamental Analysis - Y-MABS THERAPEUTICS INC

Fundamental Rating

We assign a fundamental rating of 4 out of 10 to YMAB. YMAB was compared to 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for YMAB as it has an excellent financial health rating, but there are worries on the profitability. YMAB is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

YMAB had negative earnings in the past year.

In the past year YMAB has reported a negative cash flow from operations.

YMAB had negative earnings in each of the past 5 years.

YMAB had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

YMAB's Return On Assets of -18.96% is fine compared to the rest of the industry. YMAB outperforms 77.59% of its industry peers.

With an excellent Return On Equity value of -25.40%, YMAB belongs to the best of the industry, outperforming 80.74% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-18.96%
ROE	-25.4%
ROIC	N/A

ROA(3y)-36.35%

ROA(5y)-45.09%

ROE(3y)-46.99%

ROE(5y)-56.89%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

YMAB's Gross Margin of 81.78% is amongst the best of the industry. YMAB outperforms 85.37% of its industry peers.

In the last couple of years the Gross Margin of YMAB has declined.

The Profit Margin and Operating Margin are not available for YMAB so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	81.78%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-3.89%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

YMAB does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, YMAB has more shares outstanding

Compared to 5 years ago, YMAB has more shares outstanding

There is no outstanding debt for YMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

An Altman-Z score of 2.71 indicates that YMAB is not a great score, but indicates only limited risk for bankruptcy at the moment.

With a decent Altman-Z score value of 2.71, YMAB is doing good in the industry, outperforming 69.81% of the companies in the same industry.

There is no outstanding debt for YMAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	2.71

ROIC/WACCN/A

WACC9.9%

2.3 Liquidity

YMAB has a Current Ratio of 4.00. This indicates that YMAB is financially healthy and has no problem in meeting its short term obligations.

YMAB has a Current ratio of 4.00. This is comparable to the rest of the industry: YMAB outperforms 45.74% of its industry peers.

A Quick Ratio of 3.58 indicates that YMAB has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 3.58, YMAB is in line with its industry, outperforming 43.89% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	4
Quick Ratio	3.58

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

YMAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.71%, which is quite good.

Looking at the last year, YMAB shows a decrease in Revenue. The Revenue has decreased by -1.34% in the last year.

Measured over the past years, YMAB shows a very strong growth in Revenue. The Revenue has been growing by 35.95% on average per year.

EPS 1Y (TTM)10.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.67%

Revenue 1Y (TTM)-1.34%

Revenue growth 3Y35.95%

Revenue growth 5YN/A

Sales Q2Q%-14.36%

3.2 Future

Based on estimates for the next years, YMAB will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.75% on average per year.

The Revenue is expected to grow by 17.88% on average over the next years. This is quite good.

EPS Next Y-24.97%

EPS Next 2Y-19.37%

EPS Next 3Y-17.71%

EPS Next 5Y9.75%

Revenue Next Year-5.98%

Revenue Next 2Y3.28%

Revenue Next 3Y6.75%

Revenue Next 5Y17.88%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

YMAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.

Also next year YMAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as YMAB's earnings are expected to decrease with -17.71% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-19.37%

EPS Next 3Y-17.71%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

YMAB does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

Y-MABS THERAPEUTICS INC

NASDAQ:YMAB (9/15/2025, 8:00:02 PM)

After market: 8.61 0 (0%)

8.61

+0.02 (+0.23%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)08-08 2025-08-08/bmo

Earnings (Next)11-06 2025-11-06/amc

Inst Owners82.83%

Inst Owner Change-99.41%

Ins Owners0.34%

Ins Owner Change-991.55%

Market Cap391.24M

Revenue(TTM)85.39M

Net Income(TTM)-22.22M

Analysts53.75

Price Target8.2 (-4.76%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)2

Avg EPS beat(2)59.27%

Min EPS beat(2)44.37%

Max EPS beat(2)74.16%

EPS beat(4)3

Avg EPS beat(4)25.03%

Min EPS beat(4)-18.84%

Max EPS beat(4)74.16%

EPS beat(8)5

Avg EPS beat(8)16.37%

EPS beat(12)9

Avg EPS beat(12)28.96%

EPS beat(16)10

Avg EPS beat(16)18.43%

Revenue beat(2)2

Avg Revenue beat(2)4.3%

Min Revenue beat(2)4.07%

Max Revenue beat(2)4.54%

Revenue beat(4)2

Avg Revenue beat(4)-4.6%

Min Revenue beat(4)-22.2%

Max Revenue beat(4)4.54%

Revenue beat(8)3

Avg Revenue beat(8)-3.53%

Revenue beat(12)7

Avg Revenue beat(12)4.86%

Revenue beat(16)7

Avg Revenue beat(16)0.93%

PT rev (1m)0%

PT rev (3m)-44.03%

EPS NQ rev (1m)3.14%

EPS NQ rev (3m)22.86%

EPS NY rev (1m)0%

EPS NY rev (3m)18.15%

Revenue NQ rev (1m)0.53%

Revenue NQ rev (3m)0.02%

Revenue NY rev (1m)0.45%

Revenue NY rev (3m)0.94%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	4.58
P/FCF	N/A
P/OCF	N/A
P/B	4.47
P/tB	4.59
EV/EBITDA	N/A

EPS(TTM)-0.5

EYN/A

EPS(NY)-0.95

Fwd EYN/A

FCF(TTM)-0.39

FCFYN/A

OCF(TTM)-0.39

OCFYN/A

SpS1.88

BVpS1.93

TBVpS1.88

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-18.96%
ROE	-25.4%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	81.78%
FCFM	N/A

ROA(3y)-36.35%

ROA(5y)-45.09%

ROE(3y)-46.99%

ROE(5y)-56.89%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-3.89%

GM growth 5YN/A

F-Score4

Asset Turnover0.73

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	4
Quick Ratio	3.58
Altman-Z	2.71

F-Score4

WACC9.9%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)10.71%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.67%

EPS Next Y-24.97%

EPS Next 2Y-19.37%

EPS Next 3Y-17.71%

EPS Next 5Y9.75%

Revenue 1Y (TTM)-1.34%

Revenue growth 3Y35.95%

Revenue growth 5YN/A

Sales Q2Q%-14.36%

Revenue Next Year-5.98%

Revenue Next 2Y3.28%

Revenue Next 3Y6.75%

Revenue Next 5Y17.88%

EBIT growth 1Y9.11%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year-55.69%

EBIT Next 3Y-14.78%

EBIT Next 5YN/A

FCF growth 1Y60.83%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y61.1%

OCF growth 3YN/A

OCF growth 5YN/A

Y-MABS THERAPEUTICS INC / YMAB FAQ

What is the fundamental rating for YMAB stock?

ChartMill assigns a fundamental rating of 4 / 10 to YMAB.

What is the valuation status of Y-MABS THERAPEUTICS INC (YMAB) stock?

ChartMill assigns a valuation rating of 0 / 10 to Y-MABS THERAPEUTICS INC (YMAB). This can be considered as Overvalued.

Can you provide the profitability details for Y-MABS THERAPEUTICS INC?

Y-MABS THERAPEUTICS INC (YMAB) has a profitability rating of 2 / 10.

Can you provide the expected EPS growth for YMAB stock?

The Earnings per Share (EPS) of Y-MABS THERAPEUTICS INC (YMAB) is expected to decline by -24.97% in the next year.

Y-MABS THERAPEUTICS INC (YMAB) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

Y-MABS THERAPEUTICS INC / YMAB FAQ

What is the fundamental rating for YMAB stock?

What is the valuation status of Y-MABS THERAPEUTICS INC (YMAB) stock?

Can you provide the profitability details for Y-MABS THERAPEUTICS INC?

Can you provide the expected EPS growth for YMAB stock?